dociparstat
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2013 (NCT02056782)
Timeline
Indications
Mechanism of action
- Stromal cell-derived factor 1ANTAGONIST
CXCL12 antagonist
- C-X-C chemokine receptor type 4ANTAGONIST
CXCR4 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- dociparstat sodium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04571645 | Phase 3 | Jan 30, 2021 | Chimerix |
| NCT04389840 | Phase 2/Phase 3 (Phase 3) | May 31, 2020 | Chimerix |
| NCT02056782 | Phase 1 | Dec 1, 2013 | Cantex Pharmaceuticals, Translational Drug Development, University of Utah |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chimerix | For profit | 2 | 2 | 1 | 2020 |
| Cantex Pharmaceuticals | For profit | 1 | 1 | 1 | 2013 |
| Translational Drug Development | For profit | 1 | 0 | 1 | 2013 |
| University of Utah | Academic/Hospital | 1 | 0 | 1 | 2013 |
4 organizations
Page 1 / 1